• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

A novel insight into the mechanism of the antithrombotic action of defibrotide.

作者信息

Tettamanti R, Bianchi G, Vitte P A, Kato G, Porta R, Thiemermann C, Pescador R, Mantovani M

机构信息

Crinos Biological Research Laboratories, Villa Guardia, Italy.

出版信息

Life Sci. 1992;51(19):1545-55. doi: 10.1016/0024-3205(92)90565-7.

DOI:10.1016/0024-3205(92)90565-7
PMID:1331634
Abstract

Defibrotide is a polydeoxyribonucleotide sodium salt with antithrombotic properties. These properties have been attributed to its profibrinolytic activity [increase of tissue plasminogen activator (t-PA) activity, concomitant decrease of that of plasminogen activator inhibitor (PAI)], but there could conceivably be other factor(s). To look for these, we studied Defibrotide in a thrombosis model (pulmonary thromboembolism in mice) in which free radicals play a pivotal role. Defibrotide was found to be active after both intravenous and oral administration. Defibrotide behaved in vitro like a scavenger of H2O2 but not of O2.- in cell-free systems. Defibrotide added in vitro to cellular systems decreased the stimulated release of beta-glucuronidase from polymorphonuclear cells (PMNs), the luminol chemiluminescence induced by oxygen species generated by stimulated PMNs and the generation of O2.- from stimulated macrophages. We think that the antithrombotic activity of Defibrotide is based on other factor(s) in addition to profibrinolytic activity, i.e., some scavenger activity and desensitization of cells involved in thrombus formation must also be taken into account.

摘要

相似文献

1
A novel insight into the mechanism of the antithrombotic action of defibrotide.
Life Sci. 1992;51(19):1545-55. doi: 10.1016/0024-3205(92)90565-7.
2
Fibrinolytic effects of defibrotide in atherosclerotic patients.去纤苷对动脉粥样硬化患者的纤溶作用。
Semin Thromb Hemost. 1991;17 Suppl 1:101-5.
3
Defibrotide in vitro inhibits neutrophil activation by a Ca++-involving mechanism.去纤苷在体外通过一种涉及钙离子的机制抑制中性粒细胞活化。
Int J Tissue React. 1987;9(5):399-406.
4
Defibrotide reduces monocyte PAI-2 and procoagulant activity.去纤苷降低单核细胞PAI-2和促凝血活性。
Semin Thromb Hemost. 1995;21(2):245-50. doi: 10.1055/s-2007-1000400.
5
Defibrotide inhibits Ca2+ dependent neutrophil activation: implications for its pharmacological activity in vascular disorders.去纤苷抑制钙离子依赖的中性粒细胞活化:对其在血管疾病中的药理活性的影响。
Angiology. 1991 Dec;42(12):971-8. doi: 10.1177/000331979104201206.
6
The effect of defibrotide on thromboembolism in the pulmonary vasculature of mice and rabbits and in the cerebral vasculature of rabbits.去纤苷对小鼠和家兔肺血管以及家兔脑血管中血栓栓塞的影响。
Br J Pharmacol. 1993 Dec;110(4):1565-71. doi: 10.1111/j.1476-5381.1993.tb14002.x.
7
The fibrinolytic mechanism of defibrotide: effect of defibrotide on plasmin activity.去纤苷的纤溶机制:去纤苷对纤溶酶活性的影响。
Blood Coagul Fibrinolysis. 2009 Dec;20(8):627-34. doi: 10.1097/MBC.0b013e32832da1e3.
8
The pharmacology and clinical pharmacology of defibrotide: a new profibrinolytic, antithrombotic and anti-platelet substance.去纤苷的药理学与临床药理学:一种新型的促纤溶、抗血栓和抗血小板物质。
Adv Exp Med Biol. 1990;281:429-38. doi: 10.1007/978-1-4615-3806-6_46.
9
Effect of oral defibrotide on tissue-plasminogen activator and tissue-plasminogen activator inhibitor balance.口服去纤苷对组织型纤溶酶原激活物和组织型纤溶酶原激活物抑制剂平衡的影响。
Eur J Clin Pharmacol. 1992;42(4):379-83. doi: 10.1007/BF00280122.
10
Clinical pharmacology and mode of action of a new antithrombotic compound: Defibrotide.一种新型抗血栓化合物去纤苷的临床药理学及作用机制
Folia Haematol Int Mag Klin Morphol Blutforsch. 1988;115(1-2):177-80.

引用本文的文献

1
Multifactorial pathogenesis of COVID-19-related coagulopathy: Can defibrotide have a role in the early phases of coagulation disorders?新冠病毒相关凝血病的多因素发病机制:去纤苷在凝血障碍早期阶段能发挥作用吗?
J Thromb Haemost. 2020 Nov;18(11):3106-3108. doi: 10.1111/jth.15021.